Cytori Therapeutics Company Profile (NASDAQ:CYTX)

About Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CYTX
  • CUSIP: 23283K10
  • Web:
  • Market Cap: $13.54 million
  • Outstanding Shares: 34,716,000
Average Prices:
  • 50 Day Moving Avg: $0.35
  • 200 Day Moving Avg: $0.95
  • 52 Week Range: $0.28 - $2.14
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.91
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $8.75 million
  • Price / Sales: 1.55
  • Book Value: $0.34 per share
  • Price / Book: 1.15
  • EBIDTA: ($17,750,000.00)
  • Net Margins: -450.34%
  • Return on Equity: -202.62%
  • Return on Assets: -65.54%
  • Debt-to-Equity Ratio: 0.69%
  • Current Ratio: 1.18%
  • Quick Ratio: 0.86%
  • Average Volume: 824,545 shs.
  • Beta: 2.9
  • Short Ratio: 1.35

Frequently Asked Questions for Cytori Therapeutics (NASDAQ:CYTX)

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Shares of Cytori Therapeutics reverse split on the morning of Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.18) EPS for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.02. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.23 million. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The business's revenue was down 18.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.43) earnings per share. View Cytori Therapeutics' Earnings History.

When will Cytori Therapeutics make its next earnings announcement?

Cytori Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Cytori Therapeutics.

Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2017?

2 equities research analysts have issued 1 year price targets for Cytori Therapeutics' stock. Their predictions range from $2.30 to $5.00. On average, they expect Cytori Therapeutics' share price to reach $3.65 in the next twelve months. View Analyst Ratings for Cytori Therapeutics.

What are analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (7/12/2017)
  • 2. Maxim Group analysts commented, "With the closure of the Azaya acquisition announced this morning, we now assume a 15% market share and 35% royalty rate for the $300M European Liposomal Doxorubicin market with the first year of commercial sales in 2019. We recognize that a US fast track strategy could put Cytori's Doxorubicin in the US market (even before Europe) but for conservatism we do not assume US revenues in our model (nor do we assume Japan, or any other geographies which will likely evolve as well). We believe our 15% share and 35% royalty rates are both realistic (and market share could be conservative). The result of these changes is our valuation target now changes from $6 to $10 per share." (2/15/2017)

Who are some of Cytori Therapeutics' key competitors?

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the folowing people:

  • David M. Rickey, Independent Chairman of the Board
  • Marc H. Hedrick M.D., President, Chief Executive Officer, Director
  • Tiago Girao, Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
  • Seijiro N. Shirahama, President , Asia Pacific
  • John David Harris, Vice President, General Manager - Cell Therapy
  • Jeremy Bragg Hayden, Vice President - Business Development, General Counsel
  • Mark Marino M.D., Chief Medical Officer
  • Gregg A. Lapointe, Director
  • Richard James Hawkins, Independent Director
  • Gary A. Lyons, Independent Director

Who owns Cytori Therapeutics stock?

Cytori Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (2.69%) and Vanguard Group Inc. (1.89%). Company insiders that own Cytori Therapeutics stock include David Rickey, Gail K Naughton and John David Harris. View Institutional Ownership Trends for Cytori Therapeutics.

Who bought Cytori Therapeutics stock? Who is buying Cytori Therapeutics stock?

Cytori Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Vanguard Group Inc.. Company insiders that have bought Cytori Therapeutics stock in the last two years include David Rickey, Gail K Naughton and John David Harris. View Insider Buying and Selling for Cytori Therapeutics.

How do I buy Cytori Therapeutics stock?

Shares of Cytori Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytori Therapeutics' stock price today?

One share of Cytori Therapeutics stock can currently be purchased for approximately $0.39.

MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  329
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.65 (835.90% upside)

Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017B. RileyReiterated RatingNeutralMediumView Rating Details
8/11/2017Maxim GroupSet Price TargetBuy -> Buy$10.00 -> $5.00HighView Rating Details
6/28/2016Roth CapitalReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Cytori Therapeutics (NASDAQ:CYTX)
Earnings by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Earnings History by Quarter for Cytori Therapeutics (NASDAQ CYTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2017Q2 2017($0.16)($0.18)$2.23 million$0.90 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.31)($0.26)$2.32 million$0.60 millionViewN/AView Earnings Details
3/23/2017Q4 16($0.23)($0.24)$3.36 million$1.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.24)($0.26)$2.85 million$2.61 millionViewListenView Earnings Details
8/4/2016Q216($0.39)($0.43)$2.50 million$1.10 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details
3/3/2016Q4($0.04)($0.03)$2.90 million$1.56 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details
8/6/2015Q215($0.03)($0.03)$2.50 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.09)($0.12)$4.31 million$1.10 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.11)($0.15)$2.76 million$0.94 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)
2017 EPS Consensus Estimate: ($0.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cytori Therapeutics (NASDAQ:CYTX)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 11.82%
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Institutional Ownership by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016John David HarrisVPBuy2,500$2.03$5,075.00View SEC Filing  
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cytori Therapeutics (NASDAQ:CYTX)
Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
DateHeadline logoETFs with exposure to Cytori Therapeutics, Inc. : September 7, 2017 - September 7 at 5:50 PM logoCytori to restructure, cut 50% of workforce - Seeking Alpha - September 1 at 6:03 PM logoCytori Announces Corporate Restructuring & Cost Reduction Plan - September 1 at 6:03 PM logoETFs with exposure to Cytori Therapeutics, Inc. : August 25, 2017 - August 25 at 7:19 PM logoBiotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment - August 17 at 7:00 PM logoCytori Therapeutics' (CYTX) Neutral Rating Reaffirmed at B. Riley - August 16 at 10:56 PM logoHealth Care Sector Update for 08/16/2017: CYTX,IDXG,JAGX - Nasdaq - August 16 at 6:10 PM logoCytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 - August 16 at 6:10 PM logoCytori Therapeutics Inc (NASDAQ:CYTX) Given a $5.00 Price Target at Maxim Group - August 13 at 3:32 PM logoEdited Transcript of CYTX earnings conference call or presentation 10-Aug-17 9:30pm GMT - August 12 at 10:11 PM logoCytori Therapeutics' (CYTX) CEO Marc Hedrick on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 12 at 4:17 AM logoCytori Therapeutics' (NASDAQ:CYTX) "Neutral" Rating Reaffirmed at B. Riley - August 11 at 4:04 PM logoEARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q2 Earnings Report - August 11 at 12:03 AM logoCytori Therapeutics Inc (NASDAQ:CYTX) Issues Earnings Results - August 10 at 10:42 PM logoCytori Reports Second Quarter 2017 Business and Financial Results - August 10 at 7:01 PM logoInvestor Network: Cytori Therapeutics, Inc. to Host Earnings Call - August 10 at 7:01 PM logoCytori reports 2Q loss - August 10 at 7:01 PM logoCytori Therapeutics Inc (CYTX) Scheduled to Post Earnings on Thursday - August 7 at 10:48 AM logoCytori to Webcast Second Quarter Financial Results on August 10 - August 4 at 6:01 PM logoPharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case - - July 31 at 5:36 PM logoCytori Therapeutics' (CYTX) "Neutral" Rating Reaffirmed at B. Riley - July 30 at 7:14 AM logoB. Riley Downgrades Cytori Therapeutics, Inc. (CYTX) to Neutral - - July 27 at 11:13 PM logoToday's Research Reports on Stocks to Watch: Cytori Therapeutics and Novavax - July 26 at 3:51 AM logo20 Biggest Mid-Day Losers For Tuesday | Benzinga - Benzinga - July 25 at 10:47 PM logoCytori Therapeutics (CYTX) STAR Trial of Habeo Cell Therapy in Patients with Scleroderma Doesn't Met Primary Endpoint - July 24 at 10:28 PM logoAnalysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR) - July 24 at 5:26 PM logoCytori Says STAR Trial Fails To Meet Primary Or Secondary Efficacy Endpoints - July 24 at 10:47 AM logoCytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma - July 24 at 10:47 AM logoZacks Investment Research Lowers Cytori Therapeutics Inc (CYTX) to Hold - July 12 at 7:10 PM logoCytori Therapeutics Inc (NASDAQ:CYTX) Upgraded to "Buy" at Zacks Investment Research - July 11 at 9:04 PM logoCytori Therapeutics (CYTX) Says AMA Approves New Category III ... - - July 10 at 5:39 PM logoAmerican Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy - July 10 at 5:39 PM logoAre Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? - Nasdaq - July 8 at 10:07 AM logoCytori Therapeutics (CYTX) Issued Key Patents for Scleroderma - - July 8 at 10:07 AM logoAre Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? - July 8 at 10:07 AM logoPre-Open Movers 07/06: (HSNI) (BGNE) (CYTX) Higher; (EGLT) (TAHO) (AZZ) Lower (more...) - July 6 at 3:16 PM logoETFs with exposure to Cytori Therapeutics, Inc. : July 5, 2017 - July 5 at 6:27 PM logoCytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America - June 14 at 5:36 PM logoCytori Therapeutics (CYTX) Publishes Long-Term Safety Data on ... - - June 8 at 10:41 PM logoCytori Publishes Long Term Safety Data On Technology For Breast Reconstruction - June 8 at 10:06 AM logoLong Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy - June 8 at 10:06 AM logoETFs with exposure to Cytori Therapeutics, Inc. : June 6, 2017 - June 6 at 4:56 PM logoValuEngine Lowers Cytori Therapeutics Inc (CYTX) to Strong Sell - June 4 at 9:16 PM logoCytori Therapeutics Inc (CYTX) PT Set at $10.00 by Maxim Group - June 1 at 11:02 PM logoCytori to Introduce Next-Generation Celution® Technology - GlobeNewswire (press release) - June 1 at 10:17 PM logoCytori to Introduce Next-Generation Celution® Technology - June 1 at 5:16 PM logoCytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial - May 31 at 9:58 AM logoCytori Therapeutics Inc (CYTX) Short Interest Update - May 28 at 7:16 AM logoETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017 - May 25 at 6:25 PM logoCytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 - May 24 at 12:38 PM



Cytori Therapeutics (CYTX) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff